|
Study: Small Policy Changes Could Prevent Branded ‘Evergreening’
The FDA could require drugmakers seeking NDA approval on new formulations or doses on previously approved molecules to resolve outstanding patent litigation before a new approval is granted to prevent “evergreening,” or delaying of generic competition.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives